Outcomes of bictegravir/emtricitabine/tenofovir alafenamide versus efavirenz-based regimens in central China: a real-world assessment

Bibliographic Details
Main Authors: Yongquan Peng, Xujian Cao, Yating Wang, Weiwei Yu, Ziwei Zeng, Min Wang, Yanjie Yin
Format: Article
Language:English
Published: Wolters Kluwer 2023-11-01
Series:Chinese Medical Journal
Online Access:http://journals.lww.com/10.1097/CM9.0000000000002888
_version_ 1827631790835105792
author Yongquan Peng
Xujian Cao
Yating Wang
Weiwei Yu
Ziwei Zeng
Min Wang
Yanjie Yin
author_facet Yongquan Peng
Xujian Cao
Yating Wang
Weiwei Yu
Ziwei Zeng
Min Wang
Yanjie Yin
author_sort Yongquan Peng
collection DOAJ
first_indexed 2024-03-09T14:27:03Z
format Article
id doaj.art-9ed3753be00f4f4eb22ae6b1d9b2e357
institution Directory Open Access Journal
issn 0366-6999
2542-5641
language English
last_indexed 2024-03-09T14:27:03Z
publishDate 2023-11-01
publisher Wolters Kluwer
record_format Article
series Chinese Medical Journal
spelling doaj.art-9ed3753be00f4f4eb22ae6b1d9b2e3572023-11-28T07:08:38ZengWolters KluwerChinese Medical Journal0366-69992542-56412023-11-01136222738274010.1097/CM9.0000000000002888202311200-00012Outcomes of bictegravir/emtricitabine/tenofovir alafenamide versus efavirenz-based regimens in central China: a real-world assessmentYongquan Peng0Xujian Cao1Yating Wang2Weiwei Yu3Ziwei Zeng4Min Wang5Yanjie Yin1 Graduate Collaborative Training Base of the First Hospital of Changsha, University of South China, Hengyang, Hunan 421001, China1 Graduate Collaborative Training Base of the First Hospital of Changsha, University of South China, Hengyang, Hunan 421001, China1 Graduate Collaborative Training Base of the First Hospital of Changsha, University of South China, Hengyang, Hunan 421001, China2 Institute of HIV/AIDS, First Hospital of Changsha, Changsha, Hunan 410000, China.2 Institute of HIV/AIDS, First Hospital of Changsha, Changsha, Hunan 410000, China.2 Institute of HIV/AIDS, First Hospital of Changsha, Changsha, Hunan 410000, China.http://journals.lww.com/10.1097/CM9.0000000000002888
spellingShingle Yongquan Peng
Xujian Cao
Yating Wang
Weiwei Yu
Ziwei Zeng
Min Wang
Yanjie Yin
Outcomes of bictegravir/emtricitabine/tenofovir alafenamide versus efavirenz-based regimens in central China: a real-world assessment
Chinese Medical Journal
title Outcomes of bictegravir/emtricitabine/tenofovir alafenamide versus efavirenz-based regimens in central China: a real-world assessment
title_full Outcomes of bictegravir/emtricitabine/tenofovir alafenamide versus efavirenz-based regimens in central China: a real-world assessment
title_fullStr Outcomes of bictegravir/emtricitabine/tenofovir alafenamide versus efavirenz-based regimens in central China: a real-world assessment
title_full_unstemmed Outcomes of bictegravir/emtricitabine/tenofovir alafenamide versus efavirenz-based regimens in central China: a real-world assessment
title_short Outcomes of bictegravir/emtricitabine/tenofovir alafenamide versus efavirenz-based regimens in central China: a real-world assessment
title_sort outcomes of bictegravir emtricitabine tenofovir alafenamide versus efavirenz based regimens in central china a real world assessment
url http://journals.lww.com/10.1097/CM9.0000000000002888
work_keys_str_mv AT yongquanpeng outcomesofbictegraviremtricitabinetenofoviralafenamideversusefavirenzbasedregimensincentralchinaarealworldassessment
AT xujiancao outcomesofbictegraviremtricitabinetenofoviralafenamideversusefavirenzbasedregimensincentralchinaarealworldassessment
AT yatingwang outcomesofbictegraviremtricitabinetenofoviralafenamideversusefavirenzbasedregimensincentralchinaarealworldassessment
AT weiweiyu outcomesofbictegraviremtricitabinetenofoviralafenamideversusefavirenzbasedregimensincentralchinaarealworldassessment
AT ziweizeng outcomesofbictegraviremtricitabinetenofoviralafenamideversusefavirenzbasedregimensincentralchinaarealworldassessment
AT minwang outcomesofbictegraviremtricitabinetenofoviralafenamideversusefavirenzbasedregimensincentralchinaarealworldassessment
AT yanjieyin outcomesofbictegraviremtricitabinetenofoviralafenamideversusefavirenzbasedregimensincentralchinaarealworldassessment